1
|
Xu S, Liu Y, Li Y, Deng Y, Yuan J, Lv R, Wang Y, Zhang G, Guo Z, Fu D, Zeng H, Han M, Liu X. Availability of dopamine transporters in heroin-dependent subjects: A 18F-FECNT PET imaging study. Psychiatry Res Neuroimaging 2017; 263:121-126. [PMID: 28376406 DOI: 10.1016/j.pscychresns.2017.03.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Revised: 03/21/2017] [Accepted: 03/24/2017] [Indexed: 10/19/2022]
Abstract
This study was to reconfirm the reduced dopamine transporter (DAT) availability in heroin-dependent subjects and validate the use of 2β-carbomethoxy-3β-(4-chlorophenyl)-8-(2-fluoroethyl)-nortropane (18F-FECNT) as a PET radiotracer to assess the changes of striatal DAT in drug addicted subjects. Herein, we assessed DAT standardized uptake values (SUV) of 18F-FECNT in the striatum and cerebellum of 20 heroin-dependent subjects and 10 healthy controls and analyzed the correlation between DAT availability and heroin withdrawal symptom scores and anxiety/depression rating scales in heroin-dependent subjects, as well as the relationship between the withdrawal symptoms scores and age. The striatal DAT availability in heroin-dependent subjects was significantly lower (by ~15.7-17.6%) than that in healthy controls. Age was positively related to heroin withdrawal symptom scores. The withdrawal symptom scores in older patients (Age: 49.5±2.5) were significantly higher (by ~20%) than those in younger patients (Age: 30.9±4.8). These results confirm that chronic heroin use induces striatal DAT reduction, suggesting that 18F-FECNT could be used as an alternative PET imaging radioligand for in vivo imaging of DAT in drug addicted subjects. Moreover, older patients might suffer more severe withdrawal symptoms than younger patients, suggesting that older patients with heroin withdrawal could be given more medication.
Collapse
Affiliation(s)
- Shasha Xu
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China; Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Ying Liu
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China
| | - Yu Li
- Drug Rehabilitation Center, Shanghai, China
| | - Yangping Deng
- National Institute on Drug Dependence, Peking University, Beijing, China
| | - Jie Yuan
- Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Rongbin Lv
- Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Yuankai Wang
- Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Guangming Zhang
- Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Zhirui Guo
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China
| | - Daxu Fu
- Shanghai Center of Biomedicine Development, Shanghai, China
| | - Hui Zeng
- Beijing LADO Technology Company, Beijing, China
| | - Mei Han
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
| | - Xingdang Liu
- Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai, China.
| |
Collapse
|
2
|
Wang J, Hoekstra JG, Zuo C, Cook TJ, Zhang J. Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov Today 2012; 18:155-62. [PMID: 22982303 DOI: 10.1016/j.drudis.2012.09.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Revised: 08/14/2012] [Accepted: 09/05/2012] [Indexed: 01/09/2023]
Abstract
This review summarizes major advances in biomarker discovery for diagnosis, differential diagnosis and progression of Parkinson's disease (PD), with emphasis on neuroimaging and biochemical markers. Potential strategies to develop biomarkers capable of predicting PD in the prodromal stage before the appearance of motor symptoms or correlating with nonmotor symptoms, an active area of research, are also discussed.
Collapse
Affiliation(s)
- Jian Wang
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
| | | | | | | | | |
Collapse
|